What is the equivalent subcutaneous semaglutide (Ozempic) dose for a 9 mg oral semaglutide (Rybelsus) regimen?

Conversion from Oral Semaglutide 9 mg to Subcutaneous Semaglutide

There is no direct conversion from oral semaglutide (Ozempic tablets) 9 mg to subcutaneous semaglutide (Ozempic injection), as these formulations are not bioequivalent and cannot be substituted on a mg-to-mg basis. 1

Key Dosing Information

Oral Semaglutide (Ozempic Tablets)

• 9 mg oral daily is the maximum maintenance dose for the oral tablet formulation 1
• Oral bioavailability is approximately 1% due to poor GI absorption, requiring co-administration with SNAC absorption enhancer 2

Subcutaneous Semaglutide (Ozempic Injection)

• Bioavailability is ~89% 2
• Standard dosing for type 2 diabetes: 0.5 mg or 1.0 mg weekly 3
• For weight management: 2.4 mg weekly 4, 5

FDA-Approved Switching Protocol

The only FDA-approved conversion is from subcutaneous 0.5 mg weekly to oral formulations—not the reverse direction you're asking about. 1

According to FDA labeling:

• Patients on subcutaneous 0.5 mg weekly may switch to oral 4 mg or 9 mg daily
• One week after discontinuing the injection, start the oral formulation 1

Clinical Approach for Your Scenario

Since you need to convert from oral 9 mg to subcutaneous, and no official guidance exists:

Recommended Strategy:

1. Start with subcutaneous 0.5 mg weekly after discontinuing oral 9 mg

   • This is the standard maintenance dose for glycemic control 3
   • Initiate one day after the last oral dose

2. If additional glycemic control or weight loss is needed:

   • Titrate to 1.0 mg weekly after 4 weeks 3
   • For obesity management specifically, may eventually titrate to 2.4 mg weekly using standard protocol (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, each step 4 weeks apart) 6, 5

Rationale:

• Exposure levels with oral 9 mg daily are roughly comparable to subcutaneous 0.5-1.0 mg weekly based on pharmacokinetic modeling 7
• Real-world studies show comparable efficacy between oral and subcutaneous formulations at their respective approved doses 8
• The 89-fold difference in bioavailability means oral doses appear much higher numerically but deliver similar systemic exposure 2

Important Caveats

• Monitor closely for loss of glycemic control during the first 4-8 weeks after switching
• GI side effects may differ between formulations—oral semaglutide has different tolerability patterns than subcutaneous 9
• No dosage adjustments required for renal impairment with either formulation 3
• Consider patient's indication (diabetes vs. obesity) when selecting target subcutaneous dose

The conservative approach is to start at subcutaneous 0.5 mg weekly and titrate based on clinical response, rather than attempting a direct numerical conversion that doesn't exist in the evidence base.